LUCDLUCDHealthcare · Medical Devices

LUCD Stock Forecast: Lucid Diagnostics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.37
−3.45% on the day

The median 12-month analyst price target for Lucid Diagnostics, Inc. is $3. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$72.6M
Ticker Nerd rank
36/ 100
Median analyst target
$3.00
Analysts covering
4
Revenue$1.5M+26.7% y/y
Operating income−$12.8M
Net income−$11.7M
Free cash flow−$11.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−17.0%
1M
+5.9%
YTD
−65.8%
1Y
−63.5%
From 52W high
−74.6%
From 52W low
+13.6%
$0.33
$1.47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Lucid Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
36/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
80
Growth
75
Issuance
60
Revisions
34
Volatility
32
Momentum
29
Quality
21
Value
6

Accruals (80): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (6): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LUCD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LUCD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26LUCDHigh $9.50Median $3.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$2.00
Low
$3.00
Median
$9.50
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Nov 2026BTIGReiteratesBuy$2.50
23 Oct 2026BTIGReiteratesBuy$2.50
27 Aug 2026Ascendiant CapitalMaintainsBuy$9.25 → $9.50
17 Aug 2026BTIGReiteratesBuy$2.50
8 June 2026Ascendiant CapitalMaintainsBuy$9.00 → $9.25
15 May 2026BTIGReiteratesBuy—
15 May 2026Maxim GroupMaintainsBuy—
9 Apr 2026Ascendiant CapitalMaintainsBuy—
30 Mar 2026BTIGReiteratesBuy—
26 Mar 2026NeedhamReiteratesBuy—
10 Dec 2025Ascendiant CapitalMaintainsBuy—
13 Nov 2025NeedhamReiteratesBuy—
6 Oct 2025Ascendiant CapitalMaintainsBuy—
10 Sept 2025BTIGReiteratesBuy—
5 Sept 2025BTIGMaintainsBuy—
13 Aug 2025NeedhamReiteratesBuy—
16 July 2025NeedhamReiteratesBuy—
6 June 2025Ascendiant CapitalMaintainsBuy—
15 May 2025Cantor FitzgeraldReiteratesOverweight—
14 May 2025NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LUCD.

Market Radar

This page is one stock. Monday covers all of them.

LUCD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LUCD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Lucid Diagnostics, Inc. returned −63.5% against +6.9% for the S&P 500, dividends included.

LUCD vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140160Jan 26Apr 26Jul 26Oct 26LUCDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LUCD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
13.3×

Cheaper than 10% of US stocks

Price / book
12.0×

Cheaper than 6% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
2.0%

Higher than 5% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−305.6%

Higher than 5% of US stocks

Return on assets
−79.0%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lucid Diagnostics, Inc. has a market value of $72.6M and an enterprise value of $72.0M.

  • Revenue in the twelve months to 30 June 2026: $5.4M. The latest quarter grew 26.7% year on year.

  • Net income over the same four quarters: −$52.3M, a −959.8% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.45.

  • Free cash flow in the twelve months to 30 June 2026: −$47.2M.

  • Shares outstanding: 190.8M.

  • Lucid Diagnostics, Inc. employs 82 people — $66K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

LUCD and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
LUCDLucid Diagnostics, Inc.$72.6M36
SERASera Prognostics, Inc.$70.9M39
OWLTOwlet, Inc.$85.0M27
CATXPerspective Therapeutics, Inc.$91.0M11
QTRXQuanterix Corp.$92.3M53
STIMNeuronetics, Inc.$95.2M64
HYPRHyperfine, Inc.$58.0M42

Take a look at LUCD’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Lucid Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LUCD

What is the LUCD stock price forecast for 2026-2027?

The median 12-month analyst price target for Lucid Diagnostics, Inc. is $3, with estimates ranging from $2 to $9.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LUCD stock a buy right now?

Of the 4 analysts covering Lucid Diagnostics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lucid Diagnostics, Inc. 36 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LUCD?

As at 21 Nov 2026, Lucid Diagnostics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (80 of 100).

Will LUCD stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $3, and Ticker Nerd's factor model ranks Lucid Diagnostics, Inc. 36 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LUCD stock forecast for 2030?

No analyst covering Lucid Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LUCD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $9.5 over the next 12 months.

How has LUCD stock performed over the past year?

Lucid Diagnostics, Inc. returned -63.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lucid Diagnostics, Inc. do?

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease, or GERD. Its core offering centers on the EsoGuard Esophageal DNA Test, which is performed using samples collected with the EsoCheck Esophageal Cell Collection Device to help identify at-risk patients before disease progresses.

Company

About Lucid Diagnostics, Inc.

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease, or GERD. Its core offering centers on the EsoGuard Esophageal DNA Test, which is performed using samples collected with the EsoCheck Esophageal Cell Collection Device to help identify at-risk patients before disease progresses. The company’s products are designed for use in clinical settings and support physicians in screening patients who may benefit from further evaluation. Lucid Diagnostics serves the healthcare market by addressing an important unmet need in cancer prevention and risk assessment, particularly for a condition linked to highly lethal esophageal adenocarcinoma. The company is headquartered in New York, New York, and operates as a subsidiary of PAVmed Inc.

CEO Dr. Lishan Aklog M.D. · 82 employees · United States · https://www.luciddx.com